CA3029005A1 - Liponucleotide-based therapy for ards - Google Patents
Liponucleotide-based therapy for ards Download PDFInfo
- Publication number
- CA3029005A1 CA3029005A1 CA3029005A CA3029005A CA3029005A1 CA 3029005 A1 CA3029005 A1 CA 3029005A1 CA 3029005 A CA3029005 A CA 3029005A CA 3029005 A CA3029005 A CA 3029005A CA 3029005 A1 CA3029005 A1 CA 3029005A1
- Authority
- CA
- Canada
- Prior art keywords
- cdp
- composition
- choline
- ards
- dag
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662355096P | 2016-06-27 | 2016-06-27 | |
| US62/355,096 | 2016-06-27 | ||
| PCT/US2017/039545 WO2018005527A1 (en) | 2016-06-27 | 2017-06-27 | Liponucleotide-based therapy for ards |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3029005A1 true CA3029005A1 (en) | 2018-01-04 |
Family
ID=60786443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3029005A Pending CA3029005A1 (en) | 2016-06-27 | 2017-06-27 | Liponucleotide-based therapy for ards |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10874684B2 (https=) |
| EP (2) | EP4292651A3 (https=) |
| JP (1) | JP2019518798A (https=) |
| KR (1) | KR20190022682A (https=) |
| CN (1) | CN109475554A (https=) |
| AU (1) | AU2017289278A1 (https=) |
| CA (1) | CA3029005A1 (https=) |
| SG (1) | SG11201811595SA (https=) |
| WO (1) | WO2018005527A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201811595SA (en) * | 2016-06-27 | 2019-01-30 | Ohio State Innovation Foundation | Liponucleotide-based therapy for ards |
| US11154621B2 (en) | 2017-06-27 | 2021-10-26 | Ohio State Innovation Foundation | Liponucleotide-based therapy for COPD |
| EP4125857A4 (en) * | 2020-03-31 | 2024-04-17 | Diffusion Pharmaceuticals LLC | USE OF DIFFUSION ENHANCEMENT COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASE INDUCED BY VIRUSES AND BACTERIA |
| WO2021222535A1 (en) * | 2020-05-01 | 2021-11-04 | Irazu Bio | Method for treating respiratory viral infections comprising administration of fatty acid compositions |
| US20250177541A1 (en) * | 2022-03-11 | 2025-06-05 | Arizona Board Of Regents On Behalf Of Arizona State University | Pegylated serp-1 protein treatment improves outcomes after sars-cov-2 infection |
| US20250170246A1 (en) * | 2022-03-18 | 2025-05-29 | Ohio State Innovation Foundation | Cdp-choline a host-directed therapeutic for disease caused by sars cov-2 infection |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4386078A (en) * | 1980-03-03 | 1983-05-31 | The Ohio State University Research Foundation | Therapeutic agents for preventing phospholipid degradation and free fatty acid proliferation |
| CA1321994C (en) * | 1987-10-28 | 1993-09-07 | Reid Von Borstel | Acylated uridine and cytidine and uses thereof |
| US5470838A (en) * | 1987-10-28 | 1995-11-28 | Pro-Neuron, Inc. | Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine |
| JP4408450B2 (ja) * | 1994-07-01 | 2010-02-03 | ウェルスタット セラピューティクス コーポレイション | 全身性炎症および炎症性肝炎の処置のためのピリミジンヌクレオチド前駆体 |
| US6825174B2 (en) * | 1995-06-07 | 2004-11-30 | East Carolina University | Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation |
| US20030181353A1 (en) * | 1998-08-03 | 2003-09-25 | Nyce Jonathan W. | Composition & use as analgesic, anti-inflammatory, wound healing agent, for treatment of heart conditions, assessment of heart function & tissue & cell protection & healing & reperfusion, mood disorders & symptoms & sequelae of menopause & for inducing unconsciousness, sleep & anesthesia |
| US20040049022A1 (en) * | 2001-04-24 | 2004-03-11 | Nyce Jonathan W. | Composition & methods for treatment and screening |
| EP2329826A1 (en) * | 2001-07-13 | 2011-06-08 | Paratek Pharmaceuticals, Inc. | Tetracyclines for the treatment of multiple sclerosis |
| AU2002366210A1 (en) * | 2001-11-21 | 2003-06-10 | Danmarks Farmaceutiske Hojskole | Use of glycosides of mono- and diacylglycerol as anti-inflammatory agents |
| CA2587883A1 (en) * | 2004-11-17 | 2006-05-26 | Yissum Research Development Company Of The Hebrew University Of Jerusale M | Use of polymer-lipid conjugates in the prevention and treatment of chronic pulmonary disease, allergic rhinitis and asthma |
| CN101495490B (zh) * | 2005-05-23 | 2018-05-08 | 麻省理工学院 | 含有多不饱和脂肪酸和/或尿苷的组合物及其使用方法 |
| EP1888081B1 (en) | 2005-05-23 | 2016-12-28 | Massachusetts Institute of Technology | Compositions containing pufa and methods of use thereof |
| SG11201811595SA (en) * | 2016-06-27 | 2019-01-30 | Ohio State Innovation Foundation | Liponucleotide-based therapy for ards |
| US11154621B2 (en) * | 2017-06-27 | 2021-10-26 | Ohio State Innovation Foundation | Liponucleotide-based therapy for COPD |
| US11850283B2 (en) * | 2017-06-27 | 2023-12-26 | Ohio State Innovation Foundation | Liponucleotide-based therapy for asthma |
-
2017
- 2017-06-27 SG SG11201811595SA patent/SG11201811595SA/en unknown
- 2017-06-27 EP EP23207788.3A patent/EP4292651A3/en active Pending
- 2017-06-27 JP JP2019519626A patent/JP2019518798A/ja active Pending
- 2017-06-27 WO PCT/US2017/039545 patent/WO2018005527A1/en not_active Ceased
- 2017-06-27 EP EP17821089.4A patent/EP3474853A4/en not_active Withdrawn
- 2017-06-27 CN CN201780039385.4A patent/CN109475554A/zh active Pending
- 2017-06-27 AU AU2017289278A patent/AU2017289278A1/en not_active Abandoned
- 2017-06-27 KR KR1020197002042A patent/KR20190022682A/ko not_active Ceased
- 2017-06-27 CA CA3029005A patent/CA3029005A1/en active Pending
-
2018
- 2018-12-21 US US16/230,225 patent/US10874684B2/en active Active
-
2020
- 2020-11-19 US US16/952,557 patent/US20210069225A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP4292651A2 (en) | 2023-12-20 |
| US20210069225A1 (en) | 2021-03-11 |
| KR20190022682A (ko) | 2019-03-06 |
| SG11201811595SA (en) | 2019-01-30 |
| EP4292651A3 (en) | 2024-03-13 |
| US10874684B2 (en) | 2020-12-29 |
| EP3474853A1 (en) | 2019-05-01 |
| JP2019518798A (ja) | 2019-07-04 |
| AU2017289278A1 (en) | 2019-01-17 |
| EP3474853A4 (en) | 2020-02-19 |
| WO2018005527A1 (en) | 2018-01-04 |
| US20190134074A1 (en) | 2019-05-09 |
| CN109475554A (zh) | 2019-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10874684B2 (en) | Liponucleotide-based therapy for ARDS | |
| US20240245646A1 (en) | Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation | |
| US10517924B2 (en) | High density lipoprotein nanoparticles for inflammation | |
| US20210069098A1 (en) | Ribavirin perflubron emulsion composition for treating viral diseases | |
| WO2012156565A1 (es) | Preparación inyectable de melatonina | |
| US20220062425A1 (en) | Liponucleotide-based therapy for copd | |
| AU2017302617A1 (en) | Methods and compositions to treat cancer | |
| TW202203946A (zh) | 用於人或動物之慢性或急性之病毒感染症及/或敗血症之預防或治療的組成物 | |
| CN102348465A (zh) | 慢性阻塞性肺疾病改善剂 | |
| HK40003888A (en) | Liponucleotide-based therapy for ards | |
| NL2025730B1 (en) | Compounds for treatment of sepsis | |
| US20250170246A1 (en) | Cdp-choline a host-directed therapeutic for disease caused by sars cov-2 infection | |
| EP4104825A1 (en) | Pharmaceutical composition for inhibiting inflammatory response comprising hydroxyurea | |
| US20240358669A1 (en) | Methods for treating pancreatic cancer | |
| AU2022213291B2 (en) | Lipids that reduce lung damage, improve pulmonary function and decrease pro-inflammatory cytokines | |
| CN112533605A (zh) | 用于治疗癌症的组合疗法 | |
| CN110891574A (zh) | 用于预防和/或治疗肝细胞癌的美格列明 | |
| KR20230002589A (ko) | 장기 손상의 예방 및 치료 | |
| CN108601792A (zh) | 治疗细菌感染的新方法 | |
| WO2022121884A1 (zh) | 伊维菌素及其类似物在皮肤相关疾病治疗中的应用 | |
| HK40041872A (en) | Method for preventing and/or treating aging-associated cognitive impairment | |
| WO2013008681A1 (ja) | 線維症予防又は治療用医薬組成物 | |
| HK40094273A (zh) | 抗致病治疗方法 | |
| CN1739543A (zh) | 抗肿瘤化合物nobilisideA单乙酰化物脂质体静脉注射液及其制法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220627 |